Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group

Journal of Clinical Oncology

Volumn 24, Issue 29, 2006, Pages 4738-4745

  Bedikian, Agop Y ^b   Millward, Michael ^b   Pehamberger, Hubert ^b   Conry, Robert ^b   Gore, Martin ^b   Trefzer, Uwe ^b   Pavlick, Anna C ^b   DeConti, Ronald ^b   Hersh, Evan M ^b   Hersey, Peter ^b   Kirkwood, John M ^b   Haluska, Frank G ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; LACTATE DEHYDROGENASE; OBLIMERSEN; ALKYLATING AGENT; ANTISENSE OLIGONUCLEOTIDE; NUCLEOTIDE; PROTEIN BCL 2;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CATHETER INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; BLOOD; DISEASE COURSE; DRUG RESISTANCE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SKIN TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; SURVIVAL ANALYSIS; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 33750600634     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.0483     Document Type: Article

References (20)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer Statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Bajetta E, Del Vecchio M, Bernard-Marty C, et al: Metastatic melanoma: Chemotherapy. Semin Oncol 29:427-445, 2002
3. Serrone L, Zeuli M, Sega FM, et al: Dacarbazine-based chemotherapy for metastatic melanoma: Thirty-year experience overview. J Exp Clin Cancer Res 19:21-34, 2000
4. Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 22:3138-3152, 2003
5. Schmitt CA, Rosenthal CT, Lowe SW: Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6:1029-1035, 2000
6. Jansen B, Schlagbauer-Wadl H, Brown BD, et al: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-234, 1998
7. Klasa RJ, Gillum AM, Klem RE, et al: Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12:193-213, 2002
8. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A Phase III Study. J Clin Oncol 22:1118-1125, 2004
9. Chiarion Sileni V, Nortilli R, Aversa SML, et al: Phase II randomized study of dacarbazine, carmustine, cisplatin, and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res 11:189-196, 2001
10. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
11. Atzpodien J, Neuber K, Kamanabrou D, et al: Combination chemotherapy with or without sc IL-2 and IFN-alpha: Results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 86:179-184, 2002
12. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975, 1999
13. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751, 1998
14. Jansen B, Wacheck V, Heere-Ress E, et al: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-1733, 2000
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. National Cancer Institute: Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. June 1, 1999. http://ctep.cancer.gov/reporting/ etc.html
17. Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology group trials. J Clin Oncol 18:3782-3793, 2000
18. Young AM, Marsden J, Goodman A, et al: Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-α) in metastatic melanoma. Clin Oncol (R Coll Radiol) 13:458-465, 2001
19. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516-523, 1992
20. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002